BEMFOLA®, a recombinant-human Follicle Stimulating Hormone (r hFSH) commercialised by Gedeon Richter, is a biosimilar to GONAL-f®, an established reference product. BEMFOLA® is produced using recombinant DNA technology. Both BEMFOLA® and the reference product GONAL-f® are formulations of the naturally occurring hormone FSH, which plays a key role in human reproduction.
BEMFOLA®is used to treat the following groups:
- women who do not produce eggs and who do not respond to treatment with clomiphene citrate (another medicine that stimulates the ovaries to produce eggs);
- women who are undergoing assisted reproductive techniques (fertility treatment) such as in vitro fertilisation. Bemfola is given to stimulate the ovaries to produce more than one egg at a time
- women with severe deficiency (very low levels) of luteinising hormone (LH) and follicle stimulating hormone (FSH). Bemfola is given together with a medicine containing LH to stimulate the eggs to mature in the ovaries;
- men who have hypogonadotrophic hypogonadism (a rare hormone deficiency disease). Bemfola is used together with human chorionic gonadotrophin (hCG) therapy to stimulate sperm production.
BEMFOLA® is supplied in a single-use, unique, state-of-the-art delivery system which results in a simple, once-a-day disposable device, allowing the patient to self-inject. BEMFOLA® is available in 5 single use monodose presentations available in the following dosage forms: 75, 150, 225, 300 and 450 IU.
BEMFOLA® was the first biosimilar r-hFSH launched in Europe.
For further information please contact Genpharm at:
firstname.lastname@example.org or by calling +971 4 422 7010